Kodiak Sciences stock soars on positive trial results

LootboxPhobia · 2026-03-26T19:14:24+00:00

Kodiak Sciences Inc. stock price rose 26% due to the positive results of its Phase III clinical trial GLOW2 for the diabetic retinopathy treatment Zenkuda. The study showed that patients treated with Zenkuda experienced significantly greater improvement in disease severity compared to the placebo group, and the drug demonstrated good safety. The company plans to accelerate the biologics license application for Zenkuda.

LootboxPhobia

2026-03-26 19:14:24

Abstract generation in progress

Investing.com – Kodiak Sciences Inc. (NASDAQ:KOD) stock rose 26% on Thursday after the company announced positive topline results from GLOW2, its second Phase 3 study of the diabetic retinopathy treatment drug Zenkuda (tarcocimab tedromer).

In the study, 62.5% of patients treated with Zenkuda achieved a ≥2-level improvement in diabetic retinopathy severity score, compared to only 3.3% in the placebo group, reaching a statistically significant primary endpoint. At the end of the trial, all patients received injections at six-month intervals.

Zenkuda showed an 85% risk reduction in preventing vision-threatening complications, with 2.4% of Zenkuda-treated patients experiencing such complications versus 15.8% in the placebo group. The drug also demonstrated a ≥3-level improvement in diabetic retinopathy severity score in 13.7% of patients, compared to 0% in the placebo group.

The study expanded on earlier GLOW1 trial data, including patients with proliferative diabetic retinopathy and mild diabetic macular edema. GLOW2 also included patients using GLP-1 medications, with Zenkuda showing similar efficacy regardless of concurrent GLP-1 use.

In terms of safety, no cases of intraocular inflammation were observed, with cataract adverse events occurring in 2.3% of Zenkuda patients and 1.6% of placebo patients. No cases of retinal vasculitis or occlusive retinal vasculitis were reported.

Based on these results, Kodiak plans to accelerate the submission timeline for Zenkuda’s biologics license application. The company also noted that these findings are encouraging for other pipeline candidates, including KSI-501 and KSI-101, which are being evaluated in separate Phase 3 trials with results expected in 2026.

This article was translated with AI assistance. For more information, see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.